Wang et al. found that CCNA2 functions as a potential immune therapy maker in BLCA [45]; Xu et al. also confirmed that CCNA2 could activate macrophages, thus enhancing tumor immunity [46]. Here, CCNA2 is linked to bladder transitional cell carcinoma.